Publications
63 publications
Funding
10 grantsView NIH portfolio on RePORTER ↗
Active
8 grants- PIR50CA221810-09Exploiting tumor metabolism to optimize T cell therapyNational Cancer Institute · 2021–2029· 2 renewals
- Co-I1584423Targeting the melanoma metabolic microenvironment to boost T-cell therapyMelanoma Research Alliance · 2026–2029
- Co-IGHL 251782-01Effects of tumor energetics on anti-tumor immunity through vasculature remodelingThe G. Harold and Leila Y. Mathers Foundation · 2025–2028
- Co-IR01CA282889-03S1MALT1 as a rational therapeutic target in African American ancestry patients with DLBCLNational Cancer Institute · 2025–2027
- Co-ICRI13928Mechanisms of "fragile" intratumoral regulatory T cells supporting anti-tumor immunityCancer Research Institute, Inc. · 2025–2027
- Co-II17-0132Prostate Cancer Non-Neuroendocrine Lineage Plasticity: Detection Using Multimodal Integration And immunotherapeutic TargetingStarr Cancer Consortium · 2024–2026
- Co-IR01CA249294-03Image-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapyNational Cancer Institute · 2022–2026
- Co-ISRA 234221-01CD36 in breast cancerPilatus Biosciences Inc · 2025–2026Contract
Completed grants (2)
- KPBCA 225494-01Tumor-metabolism-driven therapies to overcome TNBC immune resistanceBreast Cancer Alliance Inc. · 2023–2025
- Co-ISRA 215059-02SRA with BMSBristol-Myers Squibb · 2021–2024Contract